Evidence map›Paper›PMID 35835621›Full record

ReviewMolecular aspects of medicine2023

Siglecs in allergy and asthma.

Bruce S Bochner, Jeremy A O'Sullivan, Alan T Chang, Bradford A Youngblood

Open access · greenAbstract readReview
In one paragraph

Review in Molecular aspects of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Exploring Siglecs: Potential Modulators of Immune Cells in Food Allergy and Therapeutic Applications.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Siglec-9 is an inhibitory receptor on human mast cells in vitro.The Journal of allergy and clinical immunology · 2023
    Article
  10. Review
  11. Potential Role of Moesin in Regulating Mast Cell Secretion.International journal of molecular sciences · 2023
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Bruce S BochnerDivision of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address: bruce.bochner@northwestern.edu.
Jeremy A O'SullivanDivision of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Alan T ChangAllakos Inc., San Carlos, CA, USA.
Bradford A YoungbloodAllakos Inc., San Carlos, CA, USA.
Allakos (United States) · USNorthwestern University · US

Funding

TRM and airway inflammation and remodelingU19AI070535 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROIDE, DAVID H · 2006 to 2025
$34.2M
Treating lung inflammation by targeting SiglecsP01HL107151 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI SCHNAAR, RONALD L · 2011 to 2017
$15.4M
Using siglecs and their ligands to treat allergic diseases SALTADU19AI136443 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SCHNAAR, RONALD L · 2018 to 2022
$7.6M
Exploiting Siglec-6 for targeted anti-allergy drug delivery into human mast cellsR21AI159586 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BOCHNER, BRUCE S, SCOTT, EVAN ALEXANDER · 2021 to 2022
$417k
NHLBI NIH HHS P01 HL107151NIAID NIH HHS R21 AI159586NIAID NIH HHS U19 AI070535NIAID NIH HHS U19 AI136443
6 · The paper itself

Abstract

The term "allergic diseases" encompasses several common, IgE-mediated conditions that range from being annoying to those that are life-threatening. Available treatments include active avoidance of the instigating allergen and the use of a variety of oral, inhaled, intranasal, intraocular and injected agents. While most individuals with allergies do well with existing therapies, there are still unmet therapeutic needs. Siglecs (sialic acid-binding, immunoglobulin-like lectins) are a family of single-pass transmembrane I-type lectins found on various subsets of cells, especially those of the immune system. All Siglecs have extracellular domains recognizing sialoside ligands, and most contain cytoplasmic domains with inhibitory signaling activity. This review focuses on Siglecs that likely play a role in regulating allergic and asthmatic responses, and how specific Siglecs, expressed on cells such as eosinophils and mast cells, are being targeted for therapeutic benefit.

Indexed as

AsthmaHypersensitivityAntigens, CDHumansSialic Acid Binding Immunoglobulin-like LectinsSignal TransductionAntigens, CDSialic Acid Binding Immunoglobulin-like Lectins

Identifiers

PMID35835621
PMCPMC10757266
OpenAlexW4285046069

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.